New drug combo could shrink tumors and reduce radiation side effects in nose cancer
NCT ID NCT05941741
First seen Mar 22, 2026 · Last updated Jun 20, 2026 · Updated 17 times
Summary
This phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination or standard treatment. The study measures how long patients live without the cancer coming back, overall survival, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Center, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangxi Cancer Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, Guangxi, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cadonilimab (an immune checkpoint inhibitor)
What this could lead to
If successful, this could offer a more effective and less toxic treatment option for people with advanced nasopharyngeal cancer, potentially improving survival and quality of life.
What could go wrong
This is an early-phase trial with 380 participants, so results may not apply to everyone. Adding immunotherapy can cause immune-related side effects, and the low-dose radiation might not be as effective as standard doses.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.